HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement (the "Amended Agreement") with Lind Global Asset Management XII LLC (the "Investor"), an investment fund managed by The Lind Partners, a New York-based institutional fund manager. Under the Amended Agreement, the Company will receive aggregate gross proceeds of ...

Gael Forterre, Chief Commercial Officer, Volition commented: Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection 12 HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, i.e. no false positives, the assay de ...

MADRID and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: 9th Sachs Annual Neuroscience Innovation Forum, January 11Location: Marines’ Memorial Club, San Francisco, USAPresentation type: Company presentationPresentation time: 10:35 am (PST) 44th Annual J.P. Morgan Healthcare Conference, J ...

Company Overview - VolitionRx is focused on saving lives and improving outcomes through low-cost testing in cancer, sepsis, and veterinary applications[4, 5] - The company operates with a low capex, low opex business model, emphasizing commercial partnerships and out-licensing[21] - VolitionRx leverages its IP Powerhouse with 56 patent families and a team with hundreds of years of experience[5] Commercialization and Licensing - The company received $10 million upfront and $13 million in milestone payments from an exclusive Element i+ in-house analyzer licensing partnership[29] - In 2024, Volition sold over 120,000 Nu.Q® Vet Cancer Tests & Components[40] - The company is targeting multiple licensing deals in the human space in 2026, focusing on upfront, milestone, and recurring revenue[25] Products and Market - Nu.Q® Vet is available in the United States, Europe, and Asia, detecting 76% of systemic cancers at 97% specificity[38, 40] - The company estimates a $170 million non-regulated animal testing licensing market, a $4 billion lab-developed screening/management market, and a >$3 billion ICU/ED CE Mark/FDA NETosis sales & licensing market[36] - Lung cancer screening and disease management with Nu.Q® is forecasted to reach over 3 million tests by 2035[63]

Key combination for the treatment of Small Cell Lung CancerMADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the Japanese Patent Office has issued a Decision to Grant for its patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”. Following formal grant, the patent is expected to remain in force until at leas ...

Core Insights - VolitionRx Limited has made significant progress in 2025, focusing on the commercialization of its Nu.Q® platform for human diagnostics, with key milestones achieved in cancer and sepsis detection [2][3][4] Group 1: Business Developments - The company received its first order for Nu.Q® Cancer assays for clinical certification in lung cancer and included the Nu.Q® NETs assay in a government-backed program in France for early sepsis detection, valued at approximately $7.3 million [3][4] - Volition signed two licensing agreements with major companies, Werfen and Hologic, marking a strategic move into the human diagnostics market [5] - The company is in discussions with around 10 leading diagnostic and liquid biopsy companies to secure additional licensing agreements, anticipating announcements throughout 2026 [6][7] Group 2: Financial Opportunities - The Total Addressable Markets (TAMs) for Volition's technologies are substantial, including $2.3 billion for lung cancer screening, $23 billion for multi-cancer early detection, and $2.8 billion for sepsis early detection [11] - The company aims to replicate its successful licensing strategy in the veterinary market within the human diagnostics space, with potential for diverse deal structures and recurring revenue [7][10] Group 3: Scientific and Clinical Progress - Volition's Nu.Q® NETs assay is being evaluated in over 20 hospitals across 10 countries for various clinical use cases, indicating its potential to become a routine blood test [8] - The company has achieved significant scientific advancements, including the development of a lateral flow test for quantifying nucleosomes, which aids in clinical decision-making [10] - A large-scale study demonstrated that the Nu.Q® NETs H3.1 biomarker is an independent predictor of mortality in sepsis patients, showcasing the assay's clinical relevance [10]

37.8% of voting rights present or representedAll resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the share capital) were a ...

Core Insights - VolitionRx Limited has announced a new manuscript detailing a novel method, Capture-Seq™, for detecting cancer biomarkers through the analysis of transcription factor protected cfDNA in plasma, which promises accurate and low-cost cancer tests [1][3][4] Technology and Methodology - The new method allows for the physical enrichment of ultrashort DNA fragments bound to transcription factors, achieving a 180-fold enrichment (18,000%) compared to traditional methods that lose the DNA's chromosomal context [2][4] - By isolating ultrashort transcription factor-bound DNA, Volition's technology effectively removes 99% of background DNA, addressing the challenge of interference in liquid biopsy tests for early-stage cancer [4][5] Clinical Results - In a small training cohort of 70 individuals, including 49 cancer patients, the analysis demonstrated 100% sensitivity and specificity in detecting cancer, including early-stage cases [7] Commercial Potential - The company sees significant commercial opportunities with a Total Addressable Market estimated at approximately $23 billion annually, and is actively seeking partnerships to accelerate the technology's integration and launch [9][10] Company Overview - VolitionRx is focused on advancing epigenetics and developing cost-effective blood tests for early disease detection and monitoring, with research and development activities centered in Belgium and additional offices in the U.S. and London [10][11]

Core Insights - VolitionRx Limited's Nu.Q® NETs H3.1 assay has been included in the DETECSEPS program, aimed at early detection of sepsis, which is a significant public health concern [1][3][5] - The DETECSEPS Consortium has received approximately €6.3 million (~$7.3 million) in funding from the French government as part of the France 2030 plan [1][11] - The program seeks to reduce the socio-economic burden of sepsis, which affects around 166 million people globally and resulted in 21.4 million deaths in 2021 [4][11] Company Overview - VolitionRx is a multi-national epigenetics company focused on developing blood tests for early detection and monitoring of diseases, including sepsis [22][23] - The company aims to operationalize its understanding of epigenetics in clinical practice, particularly through the use of the H3.1 biomarker [9] - Volition's collaboration with Euroimmun will utilize the IDS i10® automated analyzer for routine measurement of H3.1 levels, providing results within one hour [8][9] Industry Context - Sepsis presents a heavy social, economic, and health burden, with significant long-term complications for survivors, including high rates of re-admission and mortality [4][10] - The DETECSEPS program is expected to implement an innovative early screening strategy combining clinical scores and the Nu.Q® H3.1 biomarker, which has shown strong diagnostic performance [5][7] - The potential market for sepsis testing is substantial, with the opportunity representing a multi-billion dollar total addressable market [11]

Core Insights - VolitionRx Limited has made its first sale of Nu.Q® Cancer assays to Hospices Civils de Lyon, a leading cancer center in Europe, marking a significant milestone in the commercialization of its cancer diagnostic technology [1][3]. Company Developments - The order from Hospices Civils de Lyon is intended to complete the internal certification process before the test is introduced into routine clinical practice for cancer management [2]. - The collaboration with the Lyon team has resulted in strong scientific and clinical evidence supporting the use of Nu.Q® in managing cancer patients, particularly in Non-Small Cell Lung Cancer [3]. Product Impact - Nu.Q® Cancer technology is designed to enhance clinical decision-making by providing valuable information on survival and progression-free survival, thus improving patient outcomes [3]. - The technology aims to empower clinicians with better monitoring capabilities throughout the patient journey, ultimately supporting patient-centered care [3]. Market Position - This sale represents a major step for Volition in the human cancer diagnostics market, aligning with the company's mission to save lives through earlier detection and improved treatment monitoring [3][4]. - Volition is focused on developing cost-effective blood tests for various diseases, including cancers, which could significantly enhance early detection and patient quality of life [4].